Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
CYRX Logo

Cryoport, Inc.

CYRX

Pharmaceutical Preparations

Mkt Cap

$773.2M

PE

-14.15

Debt

$378M

Cash

$59.47M

EV

$1.092B

FCF

-$34.65M

Market Cap

$773.2M

P/E Ratio

-14.15

Debt

$378M

Cash

$59.47M

EV

$1.092B

FCF

-$34.65M
Charts data: {"Earnings":[{"time":"2014-03-30","value":-19565426},{"time":"2015-03-30","value":-12196533},{"time":"2016-03-30","value":-15057439},{"time":"2017-12-30","value":-7899001},{"time":"2018-12-30","value":-9555601},{"time":"2019-12-30","value":-18332000},{"time":"2020-12-30","value":-75029000},{"time":"2021-12-30","value":-283724000},{"time":"2022-12-30","value":-45333000}],"Sales":[{"time":"2014-03-30","value":2659943},{"time":"2015-03-30","value":3935320},{"time":"2016-03-30","value":5882199},{"time":"2017-12-30","value":11954267},{"time":"2018-12-30","value":19626453},{"time":"2019-12-30","value":33941900},{"time":"2020-12-30","value":78696000},{"time":"2021-12-30","value":222608000},{"time":"2022-12-30","value":237277000}],"Net Margins":[{"time":"2014-03-30","value":-7.355580927861988},{"time":"2015-03-30","value":-3.0992480916418486},{"time":"2016-03-30","value":-2.559831620793516},{"time":"2017-12-30","value":-0.6607683264896125},{"time":"2018-12-30","value":-0.486873557845628},{"time":"2019-12-30","value":-0.540099405159994},{"time":"2020-12-30","value":-0.9534029683846701},{"time":"2021-12-30","value":-1.2745453892043412},{"time":"2022-12-30","value":-0.19105518023238663}],"Assets":[{"time":"2014-03-30","value":1709950},{"time":"2015-03-30","value":2606649},{"time":"2016-03-30","value":5823780},{"time":"2017-12-30","value":20264111},{"time":"2018-12-30","value":56620097},{"time":"2019-12-30","value":135872538},{"time":"2020-12-30","value":552405000},{"time":"2021-12-30","value":1112970000},{"time":"2022-12-30","value":1038746000}],"Stockholders Equity":[{"time":"2014-03-30","value":-2304495},{"time":"2015-03-30","value":-416299},{"time":"2016-03-30","value":3095927},{"time":"2017-12-30","value":17886766},{"time":"2018-12-30","value":38547000},{"time":"2019-12-30","value":126281348},{"time":"2020-12-30","value":382698000},{"time":"2021-12-30","value":641828000},{"time":"2022-12-30","value":555838000}],"ROE":[{"time":"2014-03-30","value":8.490114320057106},{"time":"2015-03-30","value":29.297531341655876},{"time":"2016-03-30","value":-4.863628567469453},{"time":"2017-12-30","value":-0.44161146850134897},{"time":"2018-12-30","value":-0.24789480374607623},{"time":"2019-12-30","value":-0.14516791505899984},{"time":"2020-12-30","value":-0.19605276223027035},{"time":"2021-12-30","value":-0.44205612718672294},{"time":"2022-12-30","value":-0.08155793594536538}],"ROA":[{"time":"2014-03-30","value":-2.96989678060762},{"time":"2015-03-30","value":-2.1456789924535293},{"time":"2016-03-30","value":-1.5008973553259224},{"time":"2017-12-30","value":-0.38877427191353225},{"time":"2018-12-30","value":-0.15267750247760967},{"time":"2019-12-30","value":-0.12440321089755459},{"time":"2020-12-30","value":-0.054326083217928874},{"time":"2021-12-30","value":-0.016019299711582523},{"time":"2022-12-30","value":-0.030713957021254474}]}

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Sector

  • ABBV Logo

    ABBV

  • ABCL Logo

    ABCL

  • ABT Logo

    ABT

  • ABUS Logo

    ABUS

  • AGIO Logo

    AGIO

  • AKBA Logo

    AKBA

  • AKRO Logo

    AKRO

  • ALKS Logo

    ALKS

  • ALNY Logo

    ALNY

  • ALPN Logo

    ALPN

  • AMLX Logo

    AMLX

  • AMPH Logo

    AMPH

  • AMRN Logo

    AMRN

  • AMRX Logo

    AMRX

  • ANAB Logo

    ANAB

  • ANIP Logo

    ANIP

  • APLS Logo

    APLS

  • ARDX Logo

    ARDX

  • ARQT Logo

    ARQT

  • ARVN Logo

    ARVN

  • ARWR Logo

    ARWR

  • AUPH Logo

    AUPH

  • AVDL Logo

    AVDL

  • AVIR Logo

    AVIR

  • AVTE Logo

    AVTE

  • AXSM Logo

    AXSM

  • BBIO Logo

    BBIO

  • BCYC Logo

    BCYC

  • BGNE Logo

    BGNE

  • BHVN Logo

    BHVN

  • BMEA Logo

    BMEA

  • BMRN Logo

    BMRN

  • BMY Logo

    BMY

  • BPMC Logo

    BPMC

  • CBAY Logo

    CBAY

  • CDMO Logo

    CDMO

  • CERE Logo

    CERE

  • CMPS Logo

    CMPS

  • CNTA Logo

    CNTA

  • COGT Logo

    COGT

  • COLL Logo

    COLL

  • CORT Logo

    CORT

  • CPRX Logo

    CPRX

  • CRNX Logo

    CRNX

  • CTLT Logo

    CTLT

  • CYTK Logo

    CYTK

  • DAWN Logo

    DAWN

  • DCPH Logo

    DCPH

  • DVAX Logo

    DVAX

  • DYN Logo

    DYN

  • ELAN Logo

    ELAN

  • EOLS Logo

    EOLS

  • ETNB Logo

    ETNB

  • EWTX Logo

    EWTX

  • FOLD Logo

    FOLD

  • FULC Logo

    FULC

  • GERN Logo

    GERN

  • HRMY Logo

    HRMY

  • HROW Logo

    HROW

  • IDYA Logo

    IDYA

  • IGMS Logo

    IGMS

  • IMGN Logo

    IMGN

  • INSM Logo

    INSM

  • INVA Logo

    INVA

  • IONS Logo

    IONS

  • IRON Logo

    IRON

  • IRWD Logo

    IRWD

  • ITCI Logo

    ITCI

  • JANX Logo

    JANX

  • JAZZ Logo

    JAZZ

  • JNJ Logo

    JNJ

  • KALV Logo

    KALV

  • KNSA Logo

    KNSA

  • KROS Logo

    KROS

  • KRTX Logo

    KRTX

  • KURA Logo

    KURA

  • LFCR Logo

    LFCR

  • LGND Logo

    LGND

  • LLY Logo

    LLY

  • LQDA Logo

    LQDA

  • LXRX Logo

    LXRX

  • LYEL Logo

    LYEL

  • MDGL Logo

    MDGL

  • MGNX Logo

    MGNX

  • MIRM Logo

    MIRM

  • MLTX Logo

    MLTX

  • MNKD Logo

    MNKD

  • MORF Logo

    MORF

  • MRK Logo

    MRK

  • MRNS Logo

    MRNS

  • MRTX Logo

    MRTX

  • MRUS Logo

    MRUS

  • MRVI Logo

    MRVI

  • NATR Logo

    NATR

  • NRIX Logo

    NRIX

  • OCUL Logo

    OCUL

  • OGN Logo

    OGN

  • OLMA Logo

    OLMA

  • OPK Logo

    OPK

  • ORGO Logo

    ORGO

  • ORIC Logo

    ORIC

  • PAHC Logo

    PAHC

  • PBAJ Logo

    PBAJ

  • PBH Logo

    PBH

  • PCRX Logo

    PCRX

  • PFE Logo

    PFE

  • PGEN Logo

    PGEN

  • PHAT Logo

    PHAT

  • PLRX Logo

    PLRX

  • PNT Logo

    PNT

  • PRGO Logo

    PRGO

  • PRTA Logo

    PRTA

  • PTCT Logo

    PTCT

  • PTGX Logo

    PTGX

In the chart Earnings are multiplied by this value.

Earnings Growth -
Earnings Stability -


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years03-201403-201503-201612-201712-201812-201912-202012-202112-2022TTM
Net Margin-740%-310%-260%-66%-49%-54%-95%-130%-19%-23%
ROA-300%-210%-150%-39%-15%-12%-5.4%-1.6%-3.1%-4.7%
ROE850%2.9K%-490%-44%-25%-15%-20%-44%-8.2%-10%

What is the average Net Margin?

The average Net Margin over the past 5 years is -68.45%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -1.22%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -12.78%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is +6.49%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -25.91%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is +3.33%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years03-201403-201503-201612-201712-201812-201912-202012-202112-2022TTM
Debt FCF--0.130.000.00-2.350.00-4.84-25.65-16.98-10.91
Debt Equity-0.70-1.290.000.000.380.000.300.630.730.70
MIN
Graham Stability----------

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -10.91.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -4.56.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years03-201512-201712-201912-2021Trend
Revenue80%82%91%6.6%5.6%
Net Income-----
Stockholders Equity-99%64%-13%-75%
FCF-----

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is +81.78%.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is +5.62%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is +41.83%.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is +98.83%.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -74.96%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is +35.23%.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.